Navigation Links
Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
Date:12/1/2008

INDIANAPOLIS, Dec. 1 /PRNewswire/ -- Roche announced today that a comparative study conducted to evaluate differences in perceived pain and discomfort associated with blood glucose testing showed ACCU-CHEK blood glucose monitoring systems and lancing devices were deemed least painful.

Results indicated that, overall, the ACCU-CHEK Aviva and ACCU-CHEK Compact Plus blood glucose monitoring systems and the ACCU-CHEK Multiclix, ACCU-CHEK Softclix and ACCU-CHEK Softclix Plus lancing devices were least painful when compared to competitors. Those competitors were:

    System                   Lancing Device
    Ascensia(R) Contour(R)   Microlet(R)/Vaculance(R)
    Freestyle Freedom(R)     TheraSense(R) Freestyle(R)
    OneTouch(R) Ultra(R)2    LifeScan UltraSoft(R)

"We are pleased a recent study confirms that our products are perceived as least painful for all three testing sites included in the study-finger, palm and forearm," said Roche Director of Product Marketing Jennifer Aspy. "Our patented, precision-guided technology is what makes the difference because there is no vibration when the lancet enters or exits the skin."

Aspy added that this vibration, which occurs with conventional technology, causes side-to-side motion. This motion coupled with the lancet stopping abruptly and then bouncing back result in painful tissue damage. The technology used in the ACCU-CHEK products works in an entirely different way to greatly reduce this painful damage. ACCU-CHEK lancing devices also offer 11 depth settings, so patients can find a lancing depth to match their skin type. This customized depth penetration avoids painful nerve endings. And high-quality ACCU-CHEK lancets use comfortable, thin 28- and 30-gauge lancets with beveled tips. Lower-quality lancets use larger needles, and many lack the beveled tips, causing skin trauma.

The study consisted of 165 subjects who tested at home at least 3 times a day for 36 days, testing on each site-finger, palm and forearm-with each of the 3 competitor brands and 1 of the ACCU-CHEK products. After testing was completed, responses by subjects to the products were compared. In a second experiment in a laboratory setting, the ACCU-CHEK Multiclix and ACCU-CHEK Softclix Plus lancing devices were compared individually to competitor lancing devices.

"There is no question that better management of diabetes results in better outcomes for the patient," Aspy said. "By offering a lancing device that results in least painful testing, we are helping to remove one of the barriers to adequate testing for improved diabetes management."

The comparative pain study was conducted by Dr. Richard Koubek, of Koubek and Associates, on behalf of Roche.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management-from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's largest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Roche Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in vitro diagnostics and drugs for cancer and transplantation as well as a market leader in virology. It is also active in other major therapeutic areas, such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners-including majority ownership interests in Genentech and Chugai-and has invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Roche employs about 79,000 people. Additional information is available on the Internet at roche-diagnostics.us.

    For further information, please contact:
    Julie Vincent
    Public Relations Consultant
    Roche
    julie.vincent@roche.com
    317-521-1910

'/>"/>
SOURCE Roche Diabetes Care
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
4. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Seniors Can Be Heartened by New Study on Statins
8. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
9. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... For over twenty-four years, Doctors on Liens ... personal injury victims find high quality medical care. When the company started in 1997, ... Fast forward to present day and the now ten-page directory features a vast array of ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to host ... other developmental disabilities. The group, which is being launched with the help of Robbie ... share stories and advice, seek help, and continue their education on how to best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
Breaking Medicine News(10 mins):